Phase 1 — Early testing in a small group of people (usually 20–80) to evaluate safety, determine safe dosage, and identify side effects.
Trial locations(11 sites)
United States
UCLA Clinical & Translational Research Center (CTRC) ( Site 0006), Los Angeles, California Lucile Packard Children's Hospital ( Site 0001), Palo Alto, California University of California Davis Health ( Site 0023), Sacramento, California UCSF Medical Center at Mission Bay ( Site 0017), San Francisco, California Children's Hospital Colorado ( Site 0013), Aurora, Colorado Ann & Robert H. Lurie Children's Hospital of Chicago ( Site 0004), Chicago, Illinois University of Michigan ( Site 0014), Ann Arbor, Michigan Mayo Clinic - Rochester ( Site 0015), Rochester, Minnesota Morgan Stanley Children's Hospital ( Site 0018), New York, New York Duke University Medical Center ( Site 0008), Durham, North Carolina Cincinnati Children's Hospital Medical Center ( Site 0002), Cincinnati, Ohio